UAEs Mubadala invests in US pharma business

Abu Dhabi’s sovereign wealth fund, Mubadala, and New York-based private equity group Kohlberg will take a majority stake in the pharmaceutical company PCI Pharma Services, UAE state news agency WAM said.

Kohlberg is set to take a majority stake in the Philadelphia, US-based pharmaceutical company, while Mubadala will become a “significant investor,” WAM reported.

“Both Kohlberg and Mubadala’s experience and track record in supporting successful management teams will make a great impact on PCI’s continued journey of transformation as we focus on building capabilities to support the future demands of our biopharmaceutical customers in our shared goal of bringing life saving medicines to patients worldwide,” Chris Anderson, partner of Kohlberg said, according to WAM.

Partners Group, a global private markets investment manager, on the behalf of several clients and partners Thomas H. Lee Partners and Frazier Healthcare Partners, managed the agreement for the sale.

“Outsourced pharmaceutical services has been a key investment theme for us over the past few years, and we are excited to be partnering with one of the global leaders in this industry,” Camilla Macapili Languille, head of pharma & medtech, at Mubadala said, WAM reported.

“We have been particularly impressed by the quality and depth of PCI’s management team, as well as the company’s strong execution track record, impeccable values, and distinct vision for the long-term development of their business. We have strong conviction in the company’s growth trajectory and are committed to working with Kohlberg and Partners Group to ensure their long-term success,” she added.